metricas
covid
Buscar en
Revista Española de Patología
Toda la web
Inicio Revista Española de Patología Tumor espermatocítico variante anaplásica sincrónico bilateral: reporte de un...
Journal Information
Vol. 57. Issue 2.
Pages 146-150 (April - June 2024)
Share
Share
Download PDF
More article options
Visits
48
Vol. 57. Issue 2.
Pages 146-150 (April - June 2024)
ARTÍCULO BREVE
Tumor espermatocítico variante anaplásica sincrónico bilateral: reporte de una neoplasia infrecuente
Bilateral synchronous anaplastic variant spermatocytic tumor: Report of a rare neoplasm
Visits
48
Rosalía Sarabia Ochoa
Corresponding author
rosarao2008-12@hotmail.com

Autor para correspondencia.
, Juan Pablo García de la Torre
Servicio de Anatomía Patológica, Hospital General Universitario de Albacete, Albacete, España
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (3)
Show moreShow less
Resumen

El tumor espermatocítico es una neoplasia testicular de células germinales, muy infrecuente, que representa menos del 1% de los cánceres testiculares. Afecta generalmente a hombres mayores con una edad media de 53,6 años (rango 19-92 años).

El tumor espermatocítico se clasifica dentro del grupo de tumores germinales no relacionados con la neoplasia de células germinales in situ. Muestra características clinicopatológicas diferentes del seminoma clásico y no se considera una variante de este último. Debido a una superposición morfológica con el seminoma clásico, en el pasado se denominó «seminoma espermatocítico».

La variante anaplásica del tumor espermatocítico es excepcional, se han descrito pocos casos en la literatura, presenta un inicio más temprano en comparación con el tumor espermatocítico y un buen comportamiento a pesar de mostrar patrones histológicos similares al seminoma clásico. Presentamos el segundo caso de tumor espermatocítico anaplásico sincrónico bilateral, en un paciente joven tratado con orquiectomía y quimioterapia.

Palabras clave:
Tumor testicular
Tumor espermatocítico
Variante anaplásica
Abstract

Spermatocytic tumor is a very rare germ cell testicular neoplasm that accounts for less than 1% of testicular cancers. It generally affects older men with a mean age of 53.6 years (range 19-92 years).

Spermatocytic tumor is classified within the group of germ cell tumors not related to germ cell neoplasia in situ. It presents clinicopathological characteristics different from classic seminoma and is not considered a variant of the latter. Due to a morphologic overlap with classical seminoma, it was called “sperm cell seminoma” in the past.

The anaplastic variant of spermatocytic tumor is exceptional, few cases have been described in the literature, it presents an earlier onset compared to spermatocytic tumor and a benign behavior despite showing histological patterns similar to classic seminoma. We present the second case of bilateral synchronous anaplastic spermatocytic tumor, in a young patient treated with orchiectomy and chemotherapy.

Keywords:
Testicular tumor
Spermatocytic tumor
Anaplastic variant

Article

These are the options to access the full texts of the publication Revista Española de Patología
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Revista Española de Patología

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos